<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296905</url>
  </required_header>
  <id_info>
    <org_study_id>M13-604</org_study_id>
    <nct_id>NCT02296905</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function</brief_title>
  <official_title>Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose study designed to assess the pharmacokinetics and safety&#xD;
      of ABT-493 and/or ABT-530 in subjects with impaired hepatic function and compare them to&#xD;
      those in subjects with normal hepatic function.&#xD;
&#xD;
      Twenty-four subjects will be selected and enrolled according to the subject selection&#xD;
      criteria: 6 subjects with mild stable chronic hepatic impairment (Group I), 6 subjects with&#xD;
      moderate stable chronic hepatic impairment (Group II), 6 subjects with severe stable chronic&#xD;
      hepatic impairment (Group III) and 6 subjects with normal hepatic function (Group IV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall measurement of pharmacokinetic parameter values of ABT-493 and ABT-530</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter values include the maximum plasma concentration (Cmax), the terminal phase elimination rate constant (B), the area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall measurement of safety parameters</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>Measurement of safety parameters include physical examinations, clinical laboratory tests, 12-lead ECGs (electrocardiograms) and vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Up to 58 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal hepatic function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493</intervention_name>
    <description>Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-530</intervention_name>
    <description>Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All Subjects&#xD;
&#xD;
          -  If female, subject must be either postmenopausal for at least 2 years or surgically&#xD;
             sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).&#xD;
&#xD;
          -  Females must have negative results for pregnancy test performed:&#xD;
&#xD;
               -  At Screening on a urine specimen obtained within 28 days prior to initial study&#xD;
                  drug administration, and&#xD;
&#xD;
               -  On a serum sample obtained on Study Day -1 of Period 1.&#xD;
&#xD;
          -  Males must be surgically sterile or practicing at least one of the following methods&#xD;
             of birth control (sperm donation within the study period is not allowed):&#xD;
&#xD;
               -  Abstinence&#xD;
&#xD;
               -  Partner(s) using an Intrauterine Device (IUD)&#xD;
&#xD;
               -  Partner(s) using oral, injected, or implanted methods of hormonal contraceptives&#xD;
&#xD;
               -  Subject and/or partner(s) using double-barrier method.&#xD;
&#xD;
        Subjects with Normal Hepatic Function&#xD;
&#xD;
        In addition to the inclusion criteria above for all subjects, the following criteria must&#xD;
        be met for subjects with normal hepatic function enrolled in Group IV:&#xD;
&#xD;
          -  Judged to be in general good health based upon the results of a medical history,&#xD;
             physical examination, laboratory profile (including liver function parameters within&#xD;
             the limits of normal) and 12-lead electrocardiogram (ECG).&#xD;
&#xD;
          -  Negative hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV Ab)&#xD;
             test results.&#xD;
&#xD;
          -  Body Mass Index (BMI) is ≥ 18 to &lt; 38 kg/m2, inclusive.&#xD;
&#xD;
        Subjects with Hepatic Impairment&#xD;
&#xD;
        In addition to the inclusion criteria for all subjects, the following criteria must be met&#xD;
        for all subjects with hepatic impairment enrolled in Groups I, II and III:&#xD;
&#xD;
          -  Judged to be in stable condition and acceptable for study participation based upon the&#xD;
             results of a medical history, physical examination, laboratory profile and ECG.&#xD;
&#xD;
          -  BMI is ≥ 18 to &lt; 38 kg/m2, inclusive, for subjects with hepatic impairment without&#xD;
             ascites or subjects with subclinical ascites detected only by ultrasound or other&#xD;
             imaging. For subjects with hepatic impairment and clinically significant ascites, BMI&#xD;
             is permitted in the range between ≥ 18 to &lt; 40 kg/m2, inclusive.&#xD;
&#xD;
          -  Child-Pugh classification of Categories A (mild), B (moderate), or C (severe).&#xD;
&#xD;
          -  Medical history of chronic liver disease including and not limited to chronic&#xD;
             hepatitis B, history of alcoholic liver disease and chronic hepatitis C.&#xD;
&#xD;
          -  Presence of clinically significant hepatic impairment as indicated by either:&#xD;
&#xD;
               1. Evidence of liver cirrhosis OR&#xD;
&#xD;
               2. Medical history of at least one of the following criteria:&#xD;
&#xD;
                    -  Clinical diagnosis of liver disease&#xD;
&#xD;
                    -  Total bilirubin, &gt; 2 mg/dl, with indirect/direct ratio &lt; 1 or prolonged&#xD;
                       prothrombin time elevation &gt; 1.7 or an albumin value below the lower limit&#xD;
                       of the laboratory reference range and excluding non-hepatic causes of the&#xD;
                       previous laboratory abnormalities.&#xD;
&#xD;
        Exclusion Criteria: - History of significant sensitivity to any drug.&#xD;
&#xD;
          -  Pregnant or breastfeeding female.&#xD;
&#xD;
          -  Recent (6-month) history of drug or alcohol abuse.&#xD;
&#xD;
          -  Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM) or human&#xD;
             immunodeficiency virus antibody (HIV Ab). Negative HIV status will be confirmed at&#xD;
             Screening and the results will be maintained confidentially by the study site.&#xD;
&#xD;
          -  Detectable HCV RNA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Pugatch, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130589</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130591</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130588</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130590</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Hepatitis C Virus Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

